VectorY at a glance
We are an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives.
Antibody treatments have wide applicability in neurodegenerative diseases that are known to be complex and difficult to treat. Our cutting-edge vectorized antibody technology combines highly selective therapeutic antibodies with one-time AAV-based delivery to the CNS. We are advancing a development pipeline of potentially disease-modifying treatments for ALS, Huntington’s, and Parkinson’s disease.
Our vectorized antibody platform
Our expert team has developed a unique platform with state-of-the-art intracellular antibodies, engineered capsids and scalable AAV manufacturing processes. With this broad in-house expertise our team is uniquely positioned to rapidly discover and develop new therapies.
We have a strong pipeline of potentially disease-modifying vectorized antibody treatments for neurodegenerative diseases including ALS, Huntington’s, and Parkinson’s disease.
Our leaders on the Management Team, Board of Directors and Scientific Advisory Board have a proven track record in the development of new drugs as well as extensive business and scientific expertise.